MINA Human
Description
Introduction to MINA-Related Compounds and Entities in Human Biology
The term "MINA" appears across multiple contexts in biomedical research, referring to distinct chemical compounds, proteins, and therapeutic platforms. This article synthesizes evidence from peer-reviewed studies, clinical trials, and biochemical databases to clarify these entities and their relevance to human health.
Minaprine: A Synthetic Antidepressant Compound
IUPAC Name: N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
Molecular Formula: C₁₇H₂₂N₄O
CAS Number: 25905-77-5
Pharmacological Class: Antidepressant (ATC Code: N06AX07)
Key Properties
mdig/MINA Protein: A Ribosomal Oxygenase in Cancer
Gene Location: Chromosome 3q12.1
Protein Isoforms:
-
Isoform 1 (Canonical): 465 amino acids, 53 kDa
-
Isoform 2: 31.8 kDa
-
Isoform 3: 23.9 kDa
Functional and Clinical Insights
Molecularly Imprinted Nanoparticles Assay (MINA) for Octopamine Detection
Application: Detects octopamine (a WADA-prohibited stimulant) in urine and water.
Performance Metrics
MINA Therapeutics: RNA Activation (RNAa) Platforms
Lead Candidate: MTL-CEBPA (small activating RNA targeting C/EBP-α for liver cancer)
Clinical Trial Highlights (OUTREACH Phase I)
Isonitrosoacetone (MINA): Organophosphate Antidote
Role: Reactivates acetylcholinesterase (AChE) inhibited by nerve agents.
Reactivation Kinetics in Human AChE
Product Specs
Product Science Overview
MINA53 is a nuclear protein that is induced by the MYC oncogene. It is involved in the regulation of ribosomal RNA (rRNA) transcription and processing, which is essential for ribosome biogenesis and protein synthesis. The protein contains a JmjC domain, which is characteristic of a family of proteins known as Jumonji C (JmjC) domain-containing proteins. These proteins are known to have histone demethylase activity, which plays a role in epigenetic regulation of gene expression .
The overexpression of MYC and its target genes, including MINA53, is commonly observed in various types of cancers. MYC-induced transcriptional activation of MINA53 contributes to the oncogenic functions of MYC by promoting cell growth and proliferation. Studies have shown that MINA53 is overexpressed in several cancers, including colorectal cancer, gastric cancer, and hepatocellular carcinoma. The protein’s role in promoting ribosome biogenesis and protein synthesis is believed to be a key factor in its contribution to tumorigenesis .
Given its role in cancer, MINA53 has been identified as a potential therapeutic target. Inhibiting the function of MINA53 could potentially disrupt the MYC-driven oncogenic processes, thereby providing a strategy for cancer treatment. Research is ongoing to develop specific inhibitors that can target MINA53 and other MYC-induced proteins to combat MYC-driven cancers .
The recombinant form of MYC Induced Nuclear Antigen (Human Recombinant) is produced using recombinant DNA technology. This involves cloning the MINA gene into an expression vector, which is then introduced into a host cell, such as E. coli or mammalian cells. The host cells express the protein, which is subsequently purified for research or therapeutic use. Recombinant MINA53 is used in various studies to understand its function, regulation, and role in cancer, as well as to develop potential therapeutic interventions .
